Citations

Showing 10 of 108104 citations.

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Elassaiss‐Schaap, Jeroen , Hodi, F. Stephen , Hamid, Omid , Hwu, Wen‐Jen , Kefford, Richard , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Joseph, Richard W. , Wolchok, Jedd D. , Joshua, Anthony M. , Ribas, Antoni , Robert, Caroline , Daud, Adil , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3015-3015

10.1200/jco.2014.32.15_suppl.3015 Get It

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Hodi, F. Stephen , Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Perrone, Andrea , Gammage, Linda, Hille, Darcy A., Xue, Dahai, Kang, Soonmo Peter, Chun, Patrick, Ebbinghaus, Scot, Ribas, Antoni , Daud, Adil , Robert, Caroline , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie, Wolchok, Jedd D.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3006-3006

10.1200/jco.2014.32.15_suppl.3006 Get It

Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).
Hamid, Omid , Hodi, F. Stephen , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Patnaik, Amita , Gergich, Kevin, Li, Xiaoyun , Chun, Patrick, Ebbinghaus, Scot, Kang, Soonmo Peter, Robert, Caroline , Ribas, Antoni , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Joseph, Richard W. , Daud, Adil

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3000-3000

10.1200/jco.2014.32.15_suppl.3000 Get It

A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
Kansra, Vikram, Wilcoxen, Keith, McClure, Ty, Martell, Robert E., Agarwal, Shefali , Kurzrock, Razelle , Galanis, Evanthia , Johnson, Derek R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2092-2092

10.1200/jco.2014.32.15_suppl.2092 Get It

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
Anderson, S. Keith , Jaeckle, Kurt A. , Buckner, Jan C. , Moore, Dennis F., Ahluwalia, Manmeet S. , Lee, Eudocia Q. , Gerstner, Elizabeth R. , Lesser, Glenn J. , Prados, Michael D. , Wen, Patrick Y. , Ahluwalia, Manmeet S , Galanis, Evanthia , Miller, C. Ryan , Sarkaria, Jann N. , Ligon, Keith L , Ballman, Karla V. , Grossman, Stuart A. , Giannini, Caterina , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2030-2030

10.1200/jco.2014.32.15_suppl.2030 Get It

Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Buckner, Jan C. , Pugh, Stephanie L. , Shaw, Edward G. , Barger, Geoffrey, Coons, Stephen W., Ricci, Peter E. , Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , Brachman, David, Schultz, Christopher J. , Bahary, Jean-Paul , Fisher, Barbara J., Kim, Harold , Murtha, Albert , Curran, Walter J. , Gilbert, Mark R. , Suh, John H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2000-2000

10.1200/jco.2014.32.15_suppl.2000 Get It

Cardiovascular magnetic resonance imaging compared to echocardiogram for detecting doxorubicin-induced cardiotoxicity.
Rasool, Haleem J. , Tak, Tahir , Gill, Paula, Novotny, James Edward, Jaekel, Camilla, Elkhatib, Rifat T. , Ticku, Jonathan, Boland, Emily R, Marshall, Angus, Marshall, Angus

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1068-1068

10.1200/jco.2014.32.15_suppl.1068 Get It

Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-
Somlo, George, Frankel, Paul , Luu, Thehang, Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Chen, Alice P. , Arun, Banu , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Mortimer, Joanne , Gandara, David R. , Weitzel, Jeffrey N.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1021-1021

10.1200/jco.2014.32.15_suppl.1021 Get It

Expression of novel immunotherapeutic targets in triple-negative breast cancer.
Basu, Gargi D. , Ghazalpour, Anatole, Gatalica, Zoran , Anderson, Karen S. , McCullough, Ann E. , Spetzer, David B., Pockaj, Barbara A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1001-1001

10.1200/jco.2014.32.15_suppl.1001 Get It

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
Advani, Pooja , Dockter, Travis , Colón‐Otero, Gerardo , Perez, Edith A. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 603-603

10.1200/jco.2014.32.15_suppl.603 Get It